Professor, Molecular Medicine, Case Western Reserve University School of Medicine
Oncology
Dr. Ernest C. Borden, MD
|
|
Give Review
Ernest C. Borden is an expert in the field of Oncology. He attended Duke University School of Medicine. Duke University School of Medicine is a top medical college. Duke University School of Medicine has a rank of 8 in research and a 29 in primary care He received awards:"CMS Meaningful Use Stage 1 Certification". Ernest Borden is a published doctor. He has 50 papers published. The most current publication "Endoscopic and open surgical approaches to locally advanced sinonasal melanoma: comparing the therapeutic benefits."
Publications
- Endoscopic and open surgical approaches to locally advanced sinonasal Melanoma: comparing the therapeutic benefits.
- Dual VEGF/VEGFR inhibition in advanced solid Malignancies: Clinical effects and pharmacodynamic biomarkers.
- Prevalence of circulating tumor cells in localized prostate Cancer.
- Phase 1 Dose-Escalation Study of VB-111, an Anti-Angiogenic Virotherapy, in Patients with Advanced Solid Tumors.
- An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and Melanoma cell growth and survival.
- Thrombospondin-1 expression in Melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis.
- Phase I trials of targeted antiCancer drugs: a need to refocus.
- Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
- VB-111 for Cancer.
- Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.
- Gene Regulatory and Clinical Effects of Interferon β in Patients with Metastatic Melanoma: A Phase II Trial.
- Emerging roles of FAM14 family members (G1P3/ISG 6-16 and ISG12/IFI27) in innate immunity and Cancer.
- Interferon-stimulated genes and their protein products: what and how?
- Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung Cancer cells: correlation of resistance with IFN-stimulat...
- Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro.
- Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal st...
- Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal Tumors expre...
- Melanoma 2007: current state and preview of the future.
- G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.
- Phase II study of erlotinib in patients with Malignant pleural mesothelioma: a Southwest Oncology Group Study.
- Adult Sarcomas: a missed opportunity for sustained cooperative group translational and clinical research.
- Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b.
- Overcoming resistance to interferon-induced apoptosis of renal carcinoma and Melanoma cells by DNA demethylation.
- IFN-alpha1,8 inhibits tumor-induced angiogenesis in murine angioSarcomas.
- Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.
- Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable Soft tissue sarcoma.
- Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
- Proteomic identification of proteins conjugated to ISG15 in mouse and human cells.
- Review: Milstein Award lecture: interferons and Cancer: where from here?
- A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid Tumors.
- Metastatic uveal Melanoma.
- Estrogen and progesterone receptor expression in uterine and extrauterine leiomyoSarcomas: an immunohistochemical study.
- Reverse signaling through membrane-bound interleukin-15.
- Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17).
- Novel growth and death related interferon-stimulated genes (ISGs) in Melanoma: greater potency of IFN-beta compared with IFN-alpha2.
- Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes Neoplasms to the anti-tumor effects of Apo2L/TRAIL.
- Soft tissue sarcomas of adults: state of the translational science.
- High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction.
- Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interferon-alpha2b: gene modulatory and antigrowth effects in tumor cells.
- New and modified interferon alfas: preclinical and clinical data.
- IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis.
- Pentamidine is an inhibitor of PRL phosphatases with antiCancer activity.
- AntiCancer activity of sodium stibogluconate in synergy with IFNs.
- Molecular characterization of soft tissue Tumors.
- Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis.
- IFN-beta pretreatment sensitizes human Melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.
- Malignant melanoma: treatments emerging, but early detection is still key.
- Interferon stimulated gene 15 constitutively produced by Melanoma cells induces e-cadherin expression on human dendritic cells.
- Resistance to interferons in Melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1).
Schools
Duke University
Duke Hospital
University Penn Hospital
Johns Hopkins
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Breast Cancer
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna
- Blue Cross Blue Shield
- CareSource
- Cigna
- Commercial Insurance Company
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- Humana
- Medicaid
- Medical Mutual of Ohio
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Paramount
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Wells Fargo Insurance
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Johns Hopkins University -
University of Pennsylvania Health System -
Duke University Hospital -
Duke University School of Medicine
Hospital
-
Cleveland Clinic
Helpful Reviews
Similar Doctors
|
|
Dr. Charles J. Nock, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Alberto J. Montero, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Alok A. Khorana, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Brian J. Bolwell, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. David M. Peereboom, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Sanford D. Markowitz, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jennifer R. Eads, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Panayiotis S. Savvides, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evi Stavrou, MD |
|
|
Dr. Betty K. Hamilton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Smitha S. Krishnamurthi, MD
This Doctor is OpenDoctor Recommended.
|